hit counter
Blueprint Medicines Corporation (BPMC) Stock News Sentiment & Price - Sentifly
BPMC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Blueprint Medicines Corporation (BPMC)

USA
Biotechnology
NASDAQ
BPMC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BPMC Latest news
PRNewsWire
Neutral
Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
2021-10-21 08:00

CAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.

PRNewsWire
Neutral
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-10-05 16:01

CAMBRIDGE, Mass., Oct. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on October 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 24,068 shares of its common stock and an aggregate of 12,033  restricted stock units (RSUs) to eight new employees under Blueprint Medicines' 2020 Inducement Plan.

PRNewsWire
Neutral
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-09-03 16:01

CAMBRIDGE, Mass., Sept. 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on September 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 23,720 shares of its common stock and an aggregate of 11,858 restricted stock units (RSUs) to 12 new employees under Blueprint Medicines' 2020 Inducement Plan.

PRNewsWire
Neutral
Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-02 08:00

CAMBRIDGE, Mass. , Sept. 2, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D.

PRNewsWire
Neutral
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-08-04 16:01

CAMBRIDGE, Mass., Aug. 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on August 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 11,299 shares of its common stock and an aggregate of 5,648 restricted stock units (RSUs) to eight new employees under Blueprint Medicines' 2020 Inducement Plan.

Zacks Investment Research
Positive
Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues
2021-07-30 12:55

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

Seeking Alpha
Neutral
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2021 Results - Earnings Call Transcript
2021-07-29 15:47

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates
2021-07-29 09:53

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.09% and -4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Benzinga
Positive
Blueprint Medicines: Q2 Earnings Insights
2021-07-29 07:42

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to ($1.86), which were in line with the estimate of ($1.86).

PRNewsWire
Neutral
Blueprint Medicines Reports Second Quarter 2021 Financial Results
2021-07-29 07:00

CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2021.

Loading more news...